Severe bacterial infections are a leading cause of morbidity and mortality among people with advanced HIV disease, after tuberculosis and cryptococcal disease. For countries to reach the end-AIDS targets for 2030, there is a need to establish a roadmap for managing severe bacterial infections and re...duce mortality. The purpose of the meeting was to
Review the current research and implementation data on the use of prophylactic antibiotics (specifically azithromycin/macrolides) as part of the AHD package of care; To review options for preventing SBIs that are in line with goals of reducing AMR; Present the current evidence on diagnostics for SBI; Discuss research gaps and implementation challenges.
more
"This document has been developed for outpatient oncology
facilities to serve as a model for a basic infection
control and prevention plan. It contains policies
and procedures tailored to these settings to meet minimal
expectations of patient protections as described
in the CDC Guide to Infecti...on Prevention in Outpatient
Settings."
more
People Who Inject Drugs
In addition, the following individuals of our external expert advisory committee made instrumental contributions to the initial design and content of the document: Billy Pick, USAID; Daniel Wolfe, Open Society Foundations; Dave Burrows, AIDS Projects Management Group; Fabi...enne Hariga, United Nations Office on Drugs and Crime; Mauro Guarinieri, the Global Fund to Fight AIDS, Tuberculosis and Malaria; Richard Needle, Office of the U.S. Global AIDS Coordinator; and Sergey Votyagov, EHRN.
more
This Indicator-Based Pharmacovigilance Assessment Tool (IPAT) was developed as a comprehensive performance metric for pharmacovigilance and medicine safety systems.
La presente Nota Informativa sirve como orientación a los solicitantes que están preparando una solicitud de financiamiento del Fondo Mundial para la tuberculosis. Ofrece recomendaciones sobre cómo establecer prioridades y metas para que las intervenciones relacionadas con la tuberculosis consiga...n la máxima repercusión posible. Promueve inversiones estratégicas para salvar vidas y obtener beneficios económicos, teniendo en cuenta la situación de la tuberculosis en cada país y otros factores contextuales:
• Su perfil de tuberculosis: tanto farmacosensible como farmacorresistente.
• El contexto del sistema de salud del país.
• Los obstáculos relacionados con los derechos humanos y el género.
• Las barreras socioeconómicas y estructurales que impiden acceder a los servicios
de tuberculosis.
more
• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these... or other herbal medicines; and
• facilitate information exchange among Member States.
more
Jin et al. Military Medical Research (2020) 7:4 https://doi.org/10.1186/s40779-020-0233-6
Position Article und Guideline
El Salvador's response to tuberculosis control: A sustainability analysis
The article is a scoping review that explores the challenges in diagnosing asthma in children in three sub-Saharan African countries: Nigeria, South Africa, and Uganda. It identifies key barriers, such as a lack of community awareness, inadequate healthcare access, limited diagnostic tools like spir...ometry, and insufficient knowledge among healthcare workers. The review also highlights the stigma associated with asthma and the absence of relevant diagnostic guidelines. Solutions proposed include community education, development and adherence to diagnostic guidelines, and strengthening healthcare systems. The study aims to inform policymakers and healthcare providers to improve asthma diagnosis and care for children in these regions.
more
РУКОВОДСТВО ПО БИОЛОГИЧЕСКОЙ БЕЗОПАСНОСТИ ЛАБОРАТОРНЫХ ИССЛЕДОВАНИЙ ПРИ ТУБЕРКУЛЕЗЕ.
The development of this draft Proposed programme budget 2022–2023 comes at a unique moment for WHO. The world is in the grip of the coronavirus disease (COVID-19) pandemic and faces health, social and economic consequences on an unprecedented scale. Although it is not known when the COVID-19 pande...mic will end, recent encouraging vaccine results, in addition to the examples of countries that have achieved good results through public health measures, hold out the prospect of better days ahead. The full impact of the pandemic cannot yet be determined. But whatever its implications, the Secretariat will rise to the challenge and is ready to adapt so that it is fully equipped to support Member States for any eventuality in the future – to make sure that the world will never again have to face this kind of crisis.
more
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...rmaceutical products, including product pricing, the regulatory environment and patent status, which together shape the national hepatitis response in different settings. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
more